for AML and peripheral T-cell lymphoma (PTCL). R&D Expenses : Research and development expenses for the year ended December 31, 2024, were $19.1 million, compared to $24.0 million for the year ended ...

This randomized controlled trial is anticipated to enroll a total of 150 patients with relapsed PTCL and is evaluating soquelitinib versus physicians’ choice of either belinostat or pralatrexate.